⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ra

Every month we try and update this database with for ra cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Hepatocellular Carcinoma and Rheumatoid ArthritisNCT02880306
Carcinoma, Hepa...
RA
18 Years - 99 YearsTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)NCT01350804
Rheumatoid Arth...
AIN457
Placebo
Abatacept
18 Years - Novartis
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic SyndromesNCT00458159
Myelodysplastic...
CC-11006
18 Years - Celgene
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)NCT01350804
Rheumatoid Arth...
AIN457
Placebo
Abatacept
18 Years - Novartis
Hepatocellular Carcinoma and Rheumatoid ArthritisNCT02880306
Carcinoma, Hepa...
RA
18 Years - 99 YearsTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic SyndromesNCT00458159
Myelodysplastic...
CC-11006
18 Years - Celgene
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)NCT01350804
Rheumatoid Arth...
AIN457
Placebo
Abatacept
18 Years - Novartis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: